Here are four things to know:
1. The company’s stock currently has a consensus rating of “buy” and an average price target is $112.
2. Stryker’s most recent report showed net sales were up slightly in the third quarter of 2015. The consolidated net sales were $2.4 billion in the third quarter, a 1.3 percent increase.
3. Michael Matson, analyst at Needham, stated “We have lowered our EPS estimates given a 2016 currency headwind of $0.10-$0.15.”
4. However, corporate insider sentiment is positive on the stock, based on the recent corporate insider activity of 120 insiders.
More articles on devices:
MidCap Business Credit becomes SpineFrontier’s lending partner — 3 quick notes
OrthAlign to launch OrthAlign Plus for direct anterior hip replacement — 4 things to know
Burton’s new Outpatient LED Examination Light has arrived
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
